Search

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

204.4 0.15

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

203.9

Massimo

205

Metriche Chiave

By Trading Economics

Entrata

-23M

93M

Vendite

400K

745M

P/E

Media del settore

81.348

27.489

EPS

1.18

Rendimento da dividendi

0.37

Margine di Profitto

12.43

Dipendenti

10,030

EBITDA

-55M

201M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+11.83% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.37%

3.99%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.2B

19B

Apertura precedente

204.25

Chiusura precedente

204.4

Notizie sul Sentiment di mercato

By Acuity

38%

62%

135 / 530 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 ott 2025, 18:13 UTC

I principali Market Mover

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 ott 2025, 17:05 UTC

I principali Market Mover

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 ott 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

18 ott 2025, 07:00 UTC

Utili

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 20:34 UTC

Discorsi di Mercato

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 ott 2025, 20:27 UTC

Discorsi di Mercato

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 ott 2025, 19:46 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 ott 2025, 19:45 UTC

Discorsi di Mercato

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 ott 2025, 18:45 UTC

Discorsi di Mercato

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 ott 2025, 17:44 UTC

Discorsi di Mercato

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 ott 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 16:14 UTC

Discorsi di Mercato

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 ott 2025, 16:04 UTC

Discorsi di Mercato

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 ott 2025, 15:58 UTC

Discorsi di Mercato

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 ott 2025, 15:56 UTC

Utili

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 ott 2025, 15:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

11.83% in crescita

Previsioni per 12 mesi

Media 226.57 EUR  11.83%

Alto 240 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

135 / 530 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat